Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Fishman

Vascular Surgery Purchase, NY Medical Doctor

NPI 1437165495 CMS profile 291245

3030 Westchester Ave, Purchase, NY 10577

Open in the dashboard

General payments

$9,547

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Fishman of Purchase, NY is reported in the CMS Open Payments database as having received $9,547 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,813 26
2024 General $579 12
2023 General $2,855 22
2022 General $920 13
2021 General $681 16
2020 General $180 9
2019 General $1,519 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Fishman
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Eric Fishman were reported at $2,813. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Eric Fishman Vascular Surgery median Middle half National median
2019 $1,519 $796 $226–$2,363 $163
2020 $180 $348 $118–$1,110 $114
2021 $681 $471 $158–$1,421 $132
2022 $920 $725 $222–$2,183 $149
2023 $2,855 $836 $257–$2,440 $160
2024 $579 $909 $252–$2,619 $164
2025 $2,813 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $2,901 28 payments
  2. Terumo Medical Corporation $2,227 13 payments
  3. Medtronic, Inc. $1,859 19 payments
  4. Sirtex Medical Inc $265 3 payments
  5. Penumbra, Inc. $264 2 payments
  6. Boston Scientific Corporation $256 7 payments
  7. Cook Medical LLC $244 2 payments
  8. Medtronic Vascular, Inc. $227 4 payments
  9. Abbott Laboratories $188 3 payments
  10. Smith+Nephew, Inc. $184 8 payments
  11. Other $933 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,783 103 payments
  2. Travel and Lodging $2,264 13 payments
  3. Consulting Fee $1,500 3 payments
Products named General payments · program years 2019–2025
  1. Abre $1,778 14 payments
  2. R2P MISAGO $1,599 4 payments
  3. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $1,248 13 payments
  4. Azur CX Detachable $513 6 payments
  5. VIABAHN Endoprosthesis with PROPATEN Bioactive Surface $512 4 payments
  6. GLIDESHEATH SLENDER $351 4 payments
  7. SIR-Spheres Microspheres $265 3 payments
  8. Indigo System $264 2 payments
  9. VIABAHN VBX Balloon Expandable Endoprosthesis $258 2 payments
  10. Cook Medical Zilver PTX $244 2 payments
  11. Other $3,994 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

322

Median for Vascular Surgery: 122

Drug cost

$93,857

Median for Vascular Surgery: $14,135

Branded share of claims

88.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 68 $54,131
Xarelto Rivaroxaban Brand 15 $19,850
Brilinta Ticagrelor Brand 39 $17,611
Clopidogrel Clopidogrel Bisulfate Brand 153 $1,770
Atorvastatin Calcium Generic 25 $297
Doxycycline Hyclate Generic 11 $120
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $78

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$275,795

Medicare's payments for the services billed

Medicare patients

664

Average age 77

Services billed

1,590

314 women, 350 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Chronic kidney disease 40%
Ischemic heart disease 39%
Diabetes 37%
Heart failure 24%
COPD 22%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record